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Abstract: 
     Toxoplasma gondii is a coccidian obligatory intracellular protozoan parasite 
that utilizes cats as a definitive host and it is the causative agent of the toxoplasmosis 
(Abu-Madi, Behnke et al. 2008). The parasite affect about 30% of human population and it 
is considered a major zoonotic disease. (Chunlei Sua, Zhou et al. 2012; R. Edelhofer 2010) 
The disease is endemic in many countries in the world including Europe, United States and 
Mediterranean regions. The present study was conducted to identify immunoreactive 
Toxoplasma gondii epitopes using M13 phage display library for identifying peptides that 
mimic Toxoplasma gondii antigens. Phage display was done by plaque assay in 12 amino 
acid peptide phage library. For phage screening purposes; sera were collected from 
Toxoplasma gondii infected pregnant women, high antibody titer sera were  pooled from 
different patients after screening for anti-Toxoplasma crude antigens by Modified 
Agglutination Test (MAT). By the aid of the high antibody titer Toxoplasma gondii pooled 
sera, three screening cycles of M13 phage display library, (12 amino acids peptides) were 
achieved. In the third screening cycle; 329 reactive plaques were obtained, 138 plaques 
that gave the strongest signals with pooled sera were selected for further analysis. Reactive 
peptides were isolated and sub-cloned in recombinant expression plasmid and were used in 
dot-ELISA to screen the selected M13 phage clones with pooled sera. ELISA test was also 
carried out to detect Toxoplasma infected individuals were identified. Phage Dot-Blot 
Assay standardized for the confirmation of reactivity selected M13 phage clones with 
Toxoplasma gondii high antibody titer pooled sera and ELISA Assay revealed reactivity 
between selected amplified phages and some collected sera of Toxoplasma gondii infected 
individuals. The DNA coding the 12 amino acid peptide fused with the PIII M13 phage 
gene was amplified using specific primers flanking the peptide designed based on the PIII 
gene. DNA sequence was determined for 24 different clones, followed by bioinformatics 
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DNA analysis by means of DNA alignment and BLAST search analysis. From the 24 
sequenced peptides, 19 selected peptide clones represent the selected M13 phages showed 
no direct similarity to Toxoplasma gondii parasite DNA genomic sequences. So, due to 
that we was searching on amino acids sequence for the selected M13 phages through 
BLAST program. Data analysis showed a cross-reactivity between the selected M13 
phages and anti-Toxoplasma pooled sera; which the sequences represent the selected M13 
phages related to protozoan parasites such as Plasmodium knowlesi and Plasmodium 
fragile. These protozoan parasites are closely related to Toxoplasma family 
(Sarcocystidae). The selected M13 phage clones were pooled and tested for their reactivity 
against pooled anti-Toxoplasma sera in dot-blot and ELISA format. The obtained results 
showed specific interaction that need further studies and evaluation for the use of these 
phages in future Toxoplasma diagnosis.  
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Introduction: 
   Toxoplasmosis, is a disease that affects human and animals generally, but it has a 
stronger effect and more dangerous to women in child bearing age. Toxoplasmosis caused 
by parasite named Toxoplasma gondii that has a complex life cycle in the reproduction of 
stray cats that feed on rodents and birds, therefore that disease called toxoplasmosis. 
   Toxoplasma gondii is a coccidian obligatory intracellular protozoan parasite that 
utilizes cats as a definitive host and it is the causative agent of the toxoplasmosis disease  
(Abu-Madi, Behnke et al. 2008) .  The parasite affect about 30% of human population and 
it is considered a major zoonotic disease of human that also infects all warm-blooded 
vertebrates including mammalian and birds (Chunlei Sua, Zhou et al. 2012; R. Edelhofer 
2010).  
Furthermore, the disease is endemic in many countries in the world including 
Europe, United States and Mediterranean regions. The geographic distribution of 
toxoplasmosis varies widely between different parts of the world and attributed to climate, 
anthropogenic factors and the available water quality. Cold climate parts of the hemisphere 
have a low sero-prevalence (10-30%) compared to humid and warm climate tropical 
countries. (Mohammed 2011; Gangneux F and Drade 2012) Toxoplasmosis distribution is 
also affected by the genotype of the infecting strain, Type I Toxoplasma is highly virulent, 
while types II and III strains are less virulent. (Dalimi and Abdole  2012)  
    In addition, toxoplasmosis is considered as a public health concern mainly in 
developing countries. The disease has been reported in almost all the world that affect up 
to one third of the human population in the world including the Mediterranean regions. 
Previous studies have identified the prevalence of Toxoplasma gondii in Palestine cities 
(Hebron district, and Gaza strip), the studies showed high IgG and IgM antibody titers 
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among pregnant women. Recent data; based on some Hospital reports in Hebron city, 
indicates many abortions occur among pregnant women (personal communications).  
    In this study the development of Toxoplasma immunological test based on identification 
of immunoreactive peptides should become possible. The newly identified peptides should 
overcome the high antibody titers seen among negative controls examined by different 
imported ELISA kits. This study will allow the provision of a continuous supply of 
Toxoplasma antigenic material and in sufficient quantities. 
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1.1. History: 
        In 1908, the Toxoplasma gondii was first discovered by Nicolle and Manceaux in the 
tissues of a hamster-like rodent. (Gebremedhin 2014) At the same time in Brazil, 
Splendore (1980) described a similar parasite in a rabbit that had died with paralysis. 
Splendore erroneously identifying it as Leishmania. (Gebremedhin 2014; Sousa  2009)  
 The first case of toxoplasmosis in human was reported in 1923 by Janku who described 
the cysts in the retina of a child with congenital infection (microphtalmia and 
hydrocephalus). (Hay, Hutchison et al. 1981; Sousa 2009)  
         A fatal case of infantile granulomatous encephalitis that was identified in 1937 in 
Wolf and Cowen by Sabin and Olitski. Depending on their studies Toxoplasma gondii was 
a cause of congenital disease in Wolf and Cowen. (Sousa 2009) 
 Until 1939, the medical importance of Toxoplasma gondii remained unknown when it was 
identified in the tissues of infected infant had classic traid of symptoms (hydrocephalus, 
retinochoroiditis and intracranial calcification). (Gebremedhin 2014) The first time an 
acquired case of toxoplasmosis in a young man was described by Weinman and Pinkerton 
in 1940. (Sousa 2009) In 1948, Sabin and Feldman discovered the Toxoplasma gondii 
antibody test (dye test); which is the most serological test for toxoplasmosis to detect 
human infection. This discovery led to the recognition that the Toxoplasma gondii is a 
common parasite of warm blooded host. (Gebremedhin 2014; Sousa 2009)  
The importance of veterinary became known in 1957 when Toxoplasma gondii was 
found to cause abortion in sheep. Coccidian nature of Toxoplasma gondii came first from 
electronic microscopic examination carried out in 1960. (Gebremedhin 2014)  Hutchison 
revealed that the cat was the definitive host when he found oocysts in feline feces in 1969. 
(Sousa 2009) In 1970, the life cycle of Toxoplasma gondii was defined by the discovery of 
the sexual phase in the small intestine of cat. Toxoplasma gondii described as a major 
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cause of death in AIDS patients in 1980, 1981 and 1982; clarifying the importance of the 
immune system in controlling Toxoplasma gondii infection. (Gebremedhin 2014; Sousa 
2009) 
Nowadays the parasite is found widely distributed in the world and in warm 
blooded animals including humans. (Gebremedhin 2014) 
 
1.2. Taxonomy: 
      The phylum Apicomplexa includes pathogens that have a medical and veterinary 
importance such as Toxoplasma, Plasmodium, Neosopra and Eimeria. (Gebremedhin 
2014) 
                                 
Table 1.2.1: Taxonomy of Toxoplasma gondii parasite 
Kingdom Protista 
Subkingdom Protozoa 
Phylum Apicomplexa 
Class Sporozoasida 
Order Eucoccidiorida 
Family Sarcocystidae 
Genus Toxoplasma 
Species Gondii 
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1.3. Biology: 
1.3.1. Life cycle and transmission: 
         Toxoplasma gondii life cycle includes intestinal and extra-intestinal stages; the 
intestinal stage occurs in cats that is the only definitive host and excretes oocysts 
(Fig.1.3.1) the infective stage that passed to the environment with feces material. The 
extra-intestinal phase occurs in all infected animals including cats and produces the rapid 
multiplying tachyzoites (Fig. 1.3.2) or bradyzoites tissue pseudocysts. (Gebremedhin 2014; 
Sousa 2009) Toxoplasma gondii oocysts are shed by domestic cats for only a short period 
(1-2 Weeks) resulting in a wide spread contamination of the environment. (Dubey 2004; 
Hill and Dubey 2002) Infection by the Toxoplasma may be unrelated to direct exposure to 
a cat (Montoya, 2002), since the parasite can be transmitted horizontally i.e. ingesting 
tissue cysts or ingesting tachyzoites which are contained in raw or inadequately cooked 
infected meat, or by ingesting infectious oocysts passed cats’ feces. Vertical transmission 
route results from congenital transmission of the parasite from mother to fetus via the 
placenta. (Jaiswal, Pokherl et al. 2014) (Fig. 1.3.3) 
 
Figure 1.3.1: Toxoplasma gondii 
sporulated oocyst, Adapted from 
CDC. 
 
Figure 1.3.2: Toxoplasma gondii 
tachyzoites, Adapted from CDC. 
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Figure 1.3.3: Toxoplasma gondii parasite life cycle, Adapted from CDC. 
1.3.2. Population structure and Genotypes: 
      Highly virulent strains are obtained recently from immunocompetent patients.  
Genotyping studies on Toxoplasma gondii strains describe the population structure of 
Toxoplasma gondii as highly clonal with three main genotypes that differ dramatically in 
virulence. (Sibly, Mordue et al. 2002) Despite genetically very similar, designated as Type 
I, Type II and Type III. These types respond to the clonal population structure of 
Toxoplasma gondii and related to mouse-virulence. Since main types were found 
predominant in other continents that had  a complex population structure of Toxoplasma 
gondii; the genotypes not belonging to three main types. (Darde 2008; Sibly, Mordue et al. 
2002) Distribution of these types differ from one region to another, that observed during 
genetic analysis that shown the parasite population structure varies globally. Strains 
majority were found in North America and Europe. Type I is rarely found in America and 
Europe, while type II is dominant in North America and Europe, but type III is 
encountered in Europe. (Gebremedhin 2014) Geographic distribution of human 
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Toxoplasma gondii genotypes including congenital toxoplasmosis in the world involving 
Eurpoe, America, Africa and Asia possible relationships with human disease in 
immunocompetent individuals (table 1.3.2.1).  
 
Table 1.3.2.1: "Geographic distribution of Toxoplasma gondii genotypes in the world and 
possible relationships with human disease". (Gangneux  and Marde 2012) 
  
 
 
 
Geographical 
area 
Genotypes Specific features of human disease in 
Immunocompetent individuals and 
those with congenital toxoplasmosis 
Europe - Type II (haplogroup 2) highly 
permanent. 
- Type III, more present in South 
Europe. 
- Other genotypes sporadically 
observed. 
- Asympotomatic 
- Benign disease in immunocompetent 
individuals associated with type II or III. 
- lower rate of retinochorditis in 
immunocompetent patients and in those 
with congenital toxoplasmosis than in 
areas of South America 
North 
America 
- Type II (haplogroup 2). 
- haplogroup 12. 
- Type III ( haplogroup 3). 
- Other genotypes 
- Asympotomatic . 
- Benign disease in immunocompetent 
individuals associated with type II or III. 
- Not enough data for other haplogroups. 
South and 
Central 
America 
- High genotypic diversity. 
- Some haplogroups shared with 
Africa (haplogroup 6). 
- Type II sporadically present. 
- Type I rarely encountered. 
- Highly atypical genotypes in 
the Amazonian forest. 
- Higher rate and severity of retinochorditis 
in immunocompetent patients and in those 
with congenital toxoplasmosis 
disseminated; potentially lethal. 
- Cases observed with the most atypical 
genotypes. 
Africa - African 1, 2, 3 (haplogroup 6). 
- Type III (haplogroup 3). 
- Type II. 
- Data showed a higher rate of 
retinochorditis than in Europe 
Asia - Less genotypic diversity than in 
South America. 
- Type III (haplogroup 3). 
- A common haplogroup 
widespread across the 
continent.  
- No comparative data 
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1.3.3. Pathogenicity and Virulence: 
       Course of Toxoplasma gondii infection is determined by virulence of the Toxoplasma 
organism parasite. Strains of Toxoplasma gondii might differ in ability to cross placenta to 
cause congenital disease due to the genotypes that may differ in virulence and migratory 
capacity. 
        Type I is considered the higher virulence due to transmission, migration and 
penetration vitro biological characteristics. (Gebremedhin 2014) Type III strains are less 
virulent in mice rather than type I and II (English ED, Adomako et al. 2015); type III is 
considered as a virulent in mice, but type I leads to widespread parasite and death of mice 
and mice still survive with type II strains. (Gebremedhin 2014) Expression of virulence 
needs host response. Many virulence effectors termed core effectors in the Toxoplasma 
gondii enables Toxoplasma gondii to evade host defenses. (English ED, Adomako et al. 
2015) Type I strains associated with higher virulence in some acquired ocular diseased 
patient’s cases, but in reactivation of chronic infection in immunocompromised patients 
and with no congenital infection (through crossing placenta) indicates asymptomatic 
infection immunocompromised patients. (Weiss and Kim 2007) 
      The most prevalent in human disease, more virulent in immature fetuses and in 
immunocompromised patients is type II strains. Type II responsible for a symptomatic 
infection or benign toxoplasmosis. (Gebremedhin 2014; Weiss and Kim 2007)  Although 
there are very few reports of human disease associated with type III genotype; the type III 
may also be the case for the type II starins. (Weiss and Kim 2007) 
 
1.4. Diagnosis and Identification: 
       Cysts of Toxoplasma gondii may be visualized in tissues by the Wright -Giemsa stain, 
or by immuno-staining, which is more specific. (Conley, Jenkins et al. 1981; Goldstein, 
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Montoya et al. 2008)  The disease can be diagnosed in human by serological tests that 
includes the detection of IgM and IgG antibodies, or directly by molecular methods. 
(Paquet et al. 2013; Goldstein, Montoya et al. 2008; Hill and Dubey 2002) Clinical sings 
are not sufficient and nonspecific for a definite diagnosis. Toxoplasma gondii serological 
examination is performed using modified agglutination test (MAT). (Al-Adhamia et al. 
2016) The MAT test utilizes formalized tachyzoites and it detects only IgG antibodies as 
mercaptoethanol used in the test destroys IgM antibodies. The test has been reported to 
demonstrate high sensitivity and specificity when compared to other serological assays. 
(Shaapan et al. 2008) 
      Recent infection is confirmed by demonstrating a significant rise in IgM antibody titers 
in serum sample or by detecting toxoplasma DNA in amniotic fluid of the fetus by 
molecular techniques PCR (Goldstein, Montoya et al. 2008; Nijem and Al-Amleh 2009). 
Elevation of IgG does not distinguish between infection acquired recently or the distant 
past (Jones, Wilson et al. 2001), IgM and IgG elevated within 1 to 2 weeks of infection, in 
acute infection (Montoya, Bennett et al. 2000). The differentiation between acute and a 
chronic infection based on IgM and IgG antibodies titers is difficult to interpret, and other 
confirmatory testing is required (Paquet et al. 2013). While, toxoplasmosis screening 
during pregnancy is based on detection of specific IgG antibodies (Khammari, Saghrouni 
et al. 2013; Gangneux  and Marde 2012). In newborn serum the IgM or IgA Toxoplasma 
gondii antibodies were demonstrated to serologic diagnosis of congenital toxoplasmosis. 
(Remington, J.S et al. 2004)   
         Some commercial IgM test kits for toxoplasmosis have had problems with 
specificity, resulting in high rates of false-positive test results, and these kits have low 
specificity and the reported results are misinterpreted (Jones, Wilson et al. 2001; Montoya 
2002). False positive IgM antibody results may obtained if individual have Rheumatoid 
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factor (RF) and antinuclear antibodies (Montoya 2002; Abolghasem et al. 2011). Although 
Enzyme linked Immune-sorbent Assay (ELISA) are mostly common used, the dye test of 
Sabin and formalin is considered the gold standard for toxoplasmosis diagnosis. However, 
the dye test is complex to carry out and not suitable for routine use. (Khammari, Saghrouni 
et al., 2013; Khammari, Saghrouni, 2014) 
       Polymerase chain reaction (PCR) is a test used to detect the amniotic fluid, PCR has 
allowed earlier amniotic fluid than fetal blood sampling (Hohlfeld et al. 1994). PCR of 
amniotic fluid is more sensitive than fetal blood sampling (Foulon et al. 1999; Jones, 
Wilson et al. 2001). 
 
1.5. Treatment:  
         The world passes through complications of diseasse, so the better anti- toxoplasma 
need is necessary and urgent (Doggetta et al. 2012). The recommended therapies are based 
on extrapolations from in vitro studies, animal models mostly murine and on the clinical 
experience and practice of physicians experienced. (Weiss and Kim 2007) Current anti- 
toxoplasma drugs suppress active infection but does not cure latent infection. (Doggetta et 
al. 2012) The decision to toxoplasmosis treatment is based on the immune states of the 
patient and on the weather of the woman with acute toxoplasmosis is pregnant or not. 
(Weiss and Kim 2007) Toxoplasmosis is separated into acute, latent and congenital 
toxoplasmosis drug therapy. Spiramycin is a drug therapy for toxoplasmosis; used if 
maternal infection is occurred but the fetus is not infected with parasite (Spiramycin is 
used to prevent parasite passing through placenta from mother to fetus; which preventing 
vertical transmission).  
        Pyrimethamine and Sulfadiazine are used in state the fetus is infected. Pyrimethamine 
acts as antagonist with Sulfadiazine. The synergistically effect between these two drugs 
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results in a significant decrease in disease severity. (Paquet et al. 2013) In 
immunocompromised patients such as organ transplant recipients, AIDS patient sand 
malignancies treated with immunosuppressive or cytotoxic drugs. (Gebremedhin 2014) 
 
1.6. Epidemiology of toxoplasmosis: 
            Toxoplasmosis is found worldwide the approximately 25 to 30% of the worlds 
human population is infected. (Gangneux and Marde 2012) The geographic distribution to 
the toxoplasmosis vary widely between one country to another or even within the same 
country. This variation has been attributed to climate weather, anthropogenic factor 
including (feeding habits that consist of hand washing, method of cooking meat and 
vegetable cleaning. (Chao Yan et al. 2016) Toxoplasmosis in animals was studied by sero-
diagnosis, and it was found to be 16.10% of 205 tested cattle, 17.65% of tested sheep and 
12.09% of 306 tested goats. ( Samad et al. 1993) The disease was reported in chicken and 
cows. Other studies reported the presence of the disease in many neighboring 
Mediterranean Arab countries, Arabian Gulf countries, Turkish, Beirut, Iran and Jordan. 
(Khammari, Saghrouni et al. 2013; Jones, Wilson et al. 2001; Montoya, Bennett et al. 
2000).  The prevalence rate of the disease in Qatar targeting 823 women of childbearing 
age was found to be 35.1% and 5.2% for Toxoplasma gondii IgG and IgM, respectively. 
(Abu-Madi et al. 2010) Toxoplasmosis in Palestinian cities is considered of an important 
public health problem and the disease was proven to be endemic in Palestine, based on 
sero-prevalence studies.  In Hebron district; it was found that a total of 27.9% of the 
examined pregnant women were positive for either IgG and/or IgM antibodies. (Nijem and 
Al-Amleh 2009) While in Gaza city, the sero-prevalence rate among 312 aborted women 
was found to be 17.9% based on IgG antibodies and 12.8% based on IgM antibodies titers. 
(Al-Hindi and Lubbad 2009) Other studies in the region showed that sero-prevalence rate 
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in reproductive age women was 15.1% in Jews, 25.4% in Bedouins and 72.3% among non-
Bedouins Arabs. There is another study in two districts in Northern Palestine (Jenin and 
Tulkarm districts); the seroprevalence of Toxoplasma gondii in goats in Jenin district was 
17.44%, while in Tulkarm district was 7.69%. (Othman and Al-Zuheir 2014) In addition, 
the seroprevalence of Toxoplasma gondii in sheep, chicken and turkeys was determined by 
MAT. This study was showed the seroprevalence of the antibodies for this parasite in 4-6 
month old sheep in Beer Sheva (in the south of Palestine); which were 8.9% and 65.6% in 
older sheep. In a central region, 12% of 100 chickens in a region approximately 45Km 
north-east of Tel-Aviv and 10.5% of 57 chicken in Jerusalem were be founded seropositive 
for Toxoplasma gondii. The 45 turkeys also in a location about 56Km South east of Tel-
Aviv were founded seropositive with antibody titer ≥ 1:144 and 4 of turkeys were founded 
with antibody titer ≥ 1:50. (Salant et al. 2016)    
 
1.7. Toxoplasma gondii infection: Clinical manifestations and Control method: 
1.7.1. Clinical manifestation in human: 
          Sever disease is usually observed only in immunosuppressed individuals (AIDS) and 
in children (infected congenitally). (Baron, 1996) Encephalitis is the most clinical 
manifestation of toxoplasmosis in immunosuppressed patients; which this infection results 
from reactivation of the tissue cyst in the brain to fast growing tachyzoites. Symptoms of 
Encephalitis may include disorientation, headache, reflex changes, coma and may lead to 
death. (Baron 1996; Gebremedhin 2014) On the other hand, Lymphadenitis is the most 
common manifestation in human that includes fever, malaise, fatigue, sore throat, and 
headache and muscle pain. (Baron 1996)  
        Type II genotype is the most cases of congenital toxoplasmosis in Europe and in the 
United States. (Lindsay and Dubey 2011) Toxoplasma gondii leads to a wide spectrum of 
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clinical disease in children that infected congenitally often infect the retina and brain, 
whereas severely diseased children exhibit retinochoroiditis, convulsions, intracerebral 
calcifications and hydrocephalus sings. (Baron, 1996) 
 
1.7.2. Clinical manifestation in animals: 
      Toxoplasma gondii is not only causing severe diseases in human and has also 
capability to cause severe disease in animals. Toxoplasma gondii infection of animal can 
be important cause of abortion in goat and sheep in many countries. Cats, dogs and many 
other pet have pneumonia, encephalitis and hepatitis clinical sings that may lead to death to 
these pets due to toxoplasmosis. (Baron 1996; Gebremedhin 2014) Abortion, stillbirth and 
death in neonates clinical sings are observed in pigs. (Gebremedhin  2014) Certain species 
of avian, marsupials, hares, marsupials, hares and new world monkeys are highly 
susceptible to fatal toxoplasmosis. (Baron 1996; Gebremedhin 2014) 
 
1.7.3. Toxoplasma gondii prevention and control method: 
         Prevention of Toxoplasmosis is depended on avoiding the ingestion of tissue cysts 
and oocysts. There are three types of Toxoplasma gondii control methods, the first type is 
primary control method that is included educational materials that contain messages to 
prevent individuals from becoming infected. Especially, both pregnant women and the 
women who are becoming pregnant must be educated to avoid infection with Toxoplasma 
gondii through health care policy makers and physicians. (Goldstein, Montoya et al. 2008; 
Lopes, Goncalves et al. 2007) 
           At the first visit, health care provides the women and the immunosuppresed persons 
with the informations that include food hygiene, meat should be cooked (160˚f) and 
avoiding exposure to cat feces through wearing gloves when they are gardening or 
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handling soil. (Jones, Wilson et al. 2001; Jones and Dubey 2012) Early diagnosis of the 
mother, the fetus and the newborn refer to secondary prevention method. Avoiding actions 
that can lead to parasite transmission through placenta also consisted within the secondary 
control to toxoplasmosis. (Lopes, Goncalves et al. 2007) Tertiary control method is named 
serological screening, it is important to identify women who acquire Toxoplasma gondii 
during gestation and also to identify fetal infection through prenatal test. Tertiary 
controlling focused on early diagnosis to IgM and IgG antibodies in blood samples 
collected from the newborn. (Goldstein, Montoya et al. 2008; Lopes, Goncalves et al. 
2007) 
 
1.8. Vaccination: 
         During recent years, the research for vaccine to prevent toxoplasmosis was made, but 
it is still a little to offer against this type of parasite. Here is no vaccine to protect humans 
against toxoplasmosis. (Lopes, Goncalves et al. 2007) Human vaccination with live mutant 
or avirulent strains not be recommended because the strains may lead to risk to fetus and 
may lead to disease, especially in immunosuppressed individuals. (Jones and Dubey 2012) 
Alive Toxoplasma gondii tachyzoites vaccine is used in sheep in Europe and New Zealand. 
(Innes, Bartley et al. 2009) This vaccine produces protective immunity for 18 months to 
decrease losing of lambs. (Jones and Dubey 2012) "Toxovax" is a commercial vaccine and 
alive attenuated S48 strain in ewes and for prevention of ovine abortion, but this vaccine 
has side effects, a short shelf- life and expensive cost. This vaccine not suitable for human 
use. (Liu, Singla et al. 2012) In addition, a commercial vaccine that is used to cat no 
licensed because it has a short shelf life, high cost and must be kept frozen. (Jones and 
Dubey 2012) Alive-attenuated vaccines are able to activate MHC class 1-restricted CD
+
 T-
Cell response. On the other hand; the crude antigen vaccine, killed vaccines and in 
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activated vaccines of Toxoplasma gondii can not sufficient. DNA vaccine has advantage in 
that it can elicit humoral and cellular immune responses (CIR). This vaccine generates only 
weak immune responses when used in humans and high primates. (Liu, Singla et al. 2012) 
 
1.9. Immunity to Toxoplasma gondii: 
         When the Toxoplasma gondii infects the cell, the immune responses will be generally 
developed. Since the Toxoplasma gondii is an intracellular parasite, the infection is 
controlled by T-cell mediated immune responses and ability of CIR in resistance 
Toxoplasma gondii infection determine the survival of the host, but when the immune 
responses not able to be elicted or stimulated, the parasite will invade the host and lead to 
toxoplasmosis; which there is balance between the survival of parasite and the host cell. 
(Denkers and Gazzinelli 1998; Taweenan 2004)  
       Capacity of Toxoplasma gondii to spread in all the tissues of the host cell and the 
capacity of the recurrent infection with new strains make the immune responses against 
Toxoplasma gondii more complex. (Filisetti and Candolfi 2004) Many studies revealed that 
the Toxoplasma gondii infection controlling need pro-inflammatory production of cytokine 
IL-12 that stimulates CD4
+
, CD8
+
-Tcells and Natural  Killer (NK) to IFN-Ɣ  (gamma 
interferon). (Hunter and Sibly 2012; Johnson 1992; Gazzinelli et al. 1993) IFN-Ɣ  and 
tumor necrosis factor alpha (TNF-alpha) cytokines have ability to activate macrophage; 
which both cytokines are important in tachyzoite replication controlling during acute and 
chronic infection. (Sibley et al. 1991) IL-12 appears more important during initial infection 
and less important during chronic infection of Toxoplasma gondii. IL-12 plays a crucial 
role in activation CMI against Toxoplasma gondii. (Denkers and Gazzinelli 1998; 
Gazzinelli et al. 1994) 
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        Invasion of Toxoplasma gondii into host cell activates the innate compartment of 
immune response such as macrophages and NK cells. (Denkers and Gazzinelli 1998; 
Taweenan 2004) Macrophages play effector roles; which phagocytic cells contain on their 
surface antibodies that act as opsonion, these antibodies bind with toxoplasma antigens 
through Fab regions and bind with phagocytic cell (macrophage) through Fc region. Dead 
or opsonized parasites are degraded by lysosomal compartments, whereas live parasites 
that invade the host cell are established in protective parasitophorous vacuole (PV). 
(Hunter and Masek 2000; Mordue and 1997; Sibley, Weidner and Krahenbuhl 1985) 
Expansion of NK cell is based on CD4
+
 Lymphocytes, through the production of IL-2 
itself. NK cells classified as a major source of IFN-Ɣ . 
          Earlier studies revealed that the murine NK cells have ability to produce IFN-gamma 
when it is stimulated through co-stimulatory molecules as CD28. (Denkers and Gazzinelli 
1998) Several studies indicate that the antibodies also play a crucial role in immunity 
against Toxoplasma gondii beside the CMI responses, such as antibodies that are specific 
to SAG1 inhibit the invasion of tachyzoites into human fibroblast cells. (Mineo, Mcleod et 
al. 1993; Taweenan 2004 ) 
 
1.10. Antigens of Toxoplasma gondii: 
          The first component of Toxoplasma gondii that binds with the host cells is the 
surface antigen of parasite. (Liu, Zhang et al. 2006) Many previous studies have revealed 
that the SAG1 is  the most important ligand that binds with the host cell and is the major 
surface protein to the Toxoplasma gondii parasite. (Robinson, Smith et al. 2004) Surface 
antigens are playing essential role in neutralizing antibodies and CMI responses, such as 
SAG1 and SAG2 A that stimulate the humoral immune response in the acute infection. 
(Partanen, Turunen 1984; Séguéla, Bessieres et al. 1992) SAG1 surface protein also 
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stimulates T-cells that are producing IFN-gamma. (Khan, Eckel et al. 1988; Kim and 
Boothroyd 2005) Tachyzoite-specific antigens such as SAG1 and SAG2A and Bradyzoite-
specific antigens can activate an immune respons. (Kim and Boothroyd 2005) In humans 
suffering from chronic infection of Toxoplasmosis, the immune responses against 
bradyzoite-specific antigens, such as SAG2C/D (which is a member of SRS family) and 
SAG4, LDH2, ENO1 and P-ATPase are undetectable. (Di Cristina, Del Porto et al. 2004) 
         Apicomplexa parasites are able to invade host cells by unique mechanism involving 
secretion of secretory vesicles called transmembrane micronemal proteins (TM-MICS). 
TM- MICS play a role in host cell attachment, gliding motility, rhoptry secretion and 
invasion (Sheiner, Santos et al. 2010) In addition, TM-MICS provide the connection 
between external receptors and the submembranous acto-myosin motor that provides 
power for parasite gliding and host cell invasion. (Cérède,  Dubremetz et al. 2005)  
          The other surface protein is Rhoptries that are essential in Toxoplasma gondii 
penetration and interaction of host cell. Most ROP proteins are Apicomplexa- specific 
proteins and some of them contain enzyme signature, they are important in organelle 
function and biogenesis. (Dubremetz 2007) Toxoplasma gondii parasits have bulb of the 
rhoptry organelle that releases ROP protein when the parasite invade the host cell. (Hunter 
and Sibly 2012) According to previous studies, ROP proteins are discharged and attached 
to host cell during invasion, resulting in the prediction of effector proteins that alter the 
signals of the host cell. (Weiss and Kim 2007) When the ROP protein invade the host cell 
it can activate the signal transcription and transduction pathways (STAT) to stimulate the 
expression of cytokines and ROP protein  also binds and inactivates PV membrane. 
(Denkers, Schneider et al. 2012; Martens, Parvanova et al. 2005)  
        Dense granule proteins (GRAs) is also a soluble proteins released from dense granules 
into the PV and have two groups; the first group consists of proteins that lack homology to 
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organism and the second group consists of proteins that have homology in other 
Eukaryotes. (Rome, Beck et al. 2008) All the GRA proteins are expressed as 
excretory/secretory  antigens and composed of 25-30 amino acids except GRA3 and GRA6 
antigens; GRA3 composed of 22 amino acid and GRA6 antigen contains 23 amino acids. 
(Hung, Falcone 1996; Nam 2009) GRA proteins of Toxoplasma gondii parasite stimulate 
the maintenance of host- parasite interactions across the PV membrane. 
 
1.11. Random Phage Display Libraries Technology (RPDL): 
       Phage Display libraries is a technology for identification of epitopes or protein that 
mimic protein or non-protein epitopes and protein discovery. (Smith and Petrenko 1997; 
Wang and Yu M 2004) Applications of phage display technique are several including 
diagnostic, epitope discovery, enzyme specificity and inhibitors, agonists, antiagonists 
identification to probe, the receptor structure and function, protein-protein interactions and 
target specific antibodies generation which can be useful in specific drug delivery 
(vaccination development). (Wang and Yu M 2004)  
       Phage display is considered as the powerful methodology that includes production and 
screening a large number of random peptides of a specific length (8-20 amino acids) that 
are expressed on the surface of phages (Devlin et al. 1990) accordingly, antibodies react 
with peptides and proteins displayed on the surface of filamentous bacteriophage. 
(Morozova) 
      Initially, in 1985, George Smith performed this technology, Smith demonstrated that 
peptides on the surface of M13 bacteriophage can be expressed and affinity enrichment 
method termed "Biopanning" was developed in 1988. (Parmley and Smith 1988) 
Biopanning is the most common screening method that is based on phage clone enrichment 
with binding affinity for the target. Biopanning process involves immobilization of target 
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molecules to 96- well microtiter plates, phage binding; which the RPDL is added to the 
target coated well. Removing unbound phage, phage elution (elution of the target bound 
phage can be carried out in a solution containing free target or competing ligand) and 
amplification of eluted phage, repeating biopanning process three to six times, and 
analyzing the phage clones by DNA sequencing to identify the epitopes that bind with 
target (Pande and Szewczyk 2010). After bacterial-based amplification, the phagemids is 
collected and the relevant DNA within the interacting phage is sequenced to select the 
interacting protein fragments or interacting epitopes. 
         There are many phage display systems; the most common phage display system is 
RPDL. Success of phage display technology defined by the properties of filamentous 
bacteriophages. These bacteriophages infect gram-negative bacteria (Morozova and 
Tikunova 2009) by attaching F-pili, all coat proteins are inserted into the inner membrane 
of Escherichia coli bacteria before integrated into the phage particles (Jacobsson, Rosander 
et al. 2003). The best characterized are the M13, f1 and fd phages that infect E. coli strains 
that carry F- conjugative plasmid. (Morozova and Tikunova 2009) The genomes of f1, 
M13 and fd filamentous bacteriophages are more than 98% identical and their gene 
products interchangeable. (Pakonjac, Bennett et al. 2011) Filamentous phages have many 
features including a fixed diameter , and about 1µm long, the phage contains a circular 
single strand DNA genome that wrapped inside several copies of pv III major coat protein. 
(Wang and Yu M 2004) Phage particles are consist of five coat proteins; which are p III, 
pv III, pv I, p IX and pv II. These coat proteins are found on the surface of bacteriophage. 
(Pakonjac, Bennett et al. 2011) 
         In this study; the Ph.D. 
TM
 system or Ph.D-12 Random Peptide Phage Library (New 
England Bio Labs, Beverly, MA) was used; this system based on a simple M13 
bacteriophage vector that expresses 12 different amino acids. M13 phage libraries 
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commercially available, which present peptides at the N-terminus of the phage P III coat 
protein (these peptides displayed at one end of the filamentous phage in 3-5 copies. ( Gray 
and Brown 2013)   
One phage display technique application is cloning of DNA encoding ligand-binding 
domains of prokaryotic receptors from chromosomal DNA. This technique in identification 
of receptor gene needs for probes, so it can be used for cloning prokaryotic receptor genes 
without prior knowledge of the receptor. (Jacobsson and Frykberg 1996) Phage display 
technique is used to obtain a macromolecule proteins (peptides) that mimic the structure of 
an epitopes. These macromolecule proteins are named mimotopes. (Editorial 2001; 
Phalipon, Folgori et al. 1997) 
 
1.12. Objectives: 
       The overall aim of this study is to identify immunoreactive Toxoplasma gondii 
epitopes using random phage display library screened by human positive sera of high 
antibody titers against Toxoplasma gondii. The specific objectives are: 
 
1. Identification of high anti-Toxoplasma sera by modified agglutination test (MAT).  
 
2. Screening of  phage display peptide library by bio-panning method. 
 
3. Validation specific interaction between the selected epitopes and anti-Toxoplasma 
sera by adapting Dot-ELISA and ELISA. 
 
4. Characterization of selected epitopes by PCR, DNA sequencing and BLAST 
analysis. 
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Part 2:  Materials and Methods. 
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2.1. Serum Collection: 
       Serum samples were collected from pregnant women attending the two main Hospitals 
in Hebron district; namely (Al-Ahli hospital in Hebron and Yatta Hospital). In the last year 
(2015), an official cooperation was established with the Hospitals administrations in order 
to organize sample collection. The total number of collected samples were 204 samples.  
 
2.2. Toxoplasmosis Serodiagnosis Screening by MAT:  
        The 204 collected sera samples were screened for the presence of Toxoplasma gondii 
infection based on serological examination for collected sera. Initially, the simple Modified 
Agglutination Test (MAT), was used for direct screening and evaluation for the presence 
of IgG antibody against Toxoplasma gondii parasite. The MAT was conducted in 96-well-
U-bottomed microtiter plates. The tested sera were diluted in phosphate buffer saline 
(PBS) (1.8 mM KH2PO4, 150mM NaCl and 10.1mM Na2HPO4). Toxoplasma cells were  
prepared by mixing 150μl formalized Toxoplasma gondii tachyzoites (Reims, France), 
3.5ml antigen buffer (phosphate buffer tween), 50μl of Evans blue stain and 35μl of 2-
mercaptoethanol. Some Sera were diluted to (1:10, 1:20, 1:40, 1:80, 1:160 and 1:320) for 
MAT testing; In each (A, B, C, D, E, F, G, H)  well of microtiter plate; 90μl of serum 
diluting buffer (PBS) and 10μl of serum were added. In other wells (2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12) 50μl of antibody diluting buffer was added. 50μl of each diluted serum was 
transferred to make serial dilution. In each well of microtiter plate 50μl of Toxoplasma 
gondii antigen was mixed with antibody diluting buffer. Others sera were diluted (1:5 
and1:10) for screening the presence of toxoplasma infection. Negative control sera and 
positive control sera were included. The 96-well-U-bottomed microtiter was covered and 
incubated at room temperature for 24 hour. The collected sera samples finally were 
screened for the presence of Toxoplasma infection after incubation period based on 
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agglutination (positive result) or concentration of formalin fixed tachyzoites in the well 
bottom (negative result). (Liu, Wang et al. 2015) 
 
2.3. Antigen Preparation for immunological studies: 
       Toxoplasma gondii Antigen was prepared for SDS-PAGE Gel Electrophoresis and 
Western Blot analysis according to the following procedure: 100μl formalin fixed 
tachyzoite of Toxoplasma gondii (Reims, France) was mixed with 100μl lysis buffer of 
cells (10mM EDTA, 50mM Tris, 50mM NaCl, 0.01% SDS and PMSF Protease inhibitors 
(Sigma, USA)). Toxo- cells and lysis buffer were incubated 30 min at 60°C and kept at –
20°C for 15 min. Then incubated for 30 min at 60°C. Finally, it was centrifuged for 10 
min. Toxoplasma gondii parasite lysates containing crude antigen were frozen; crude 
antigen was thawed prior each use for SDS-PAGE Gel Electrophoresis and Western blot.  
 
2.4. SDS-PAGE Gel Electrophoresis (SDS-PAGE): 
        Firstly, 10%polyacrylamide resolving gel (1.5M Tris-HCL, pH8.8) and 5% 
polyacrylamide stacking gel (0.5 M Tris-HCL, PH6.8) were prepared. A crude antigen 
lysates of Toxoplasma gondii (protein samples) and selected amplified phages were boiled 
in water bath with loading buffer or reducing sample buffer (2.5ml glycerol, 0.2ml 0.5% 
Bromophenol Blue, 50μl 2-mercaptoethanol, 2.0ml 10% SDS, 1.25ml 0.5M Tris PH6.8 
and 3.55ml deionized water) for 10 min and separated in a SDS-Tris-glycine buffer 
through polyacrylamide gel electrophoresis (PAGE). 10μl of marker, antigen lysates-
loading buffer mixture and selected amplified phages were loaded on the SDS-PAGE Gel. 
The stacking gel was run at 50 volte (V) (20mA) and running of resolving gel (Separating 
gel) was done at 100V. Broad range Bio-Rad molecular weight markers (Land Mark 
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Prestained Protein Marker, Mbiotech) were used. (Yang and Hongbao 2009) 
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2.5. Coomassie Brilliant Blue Staining:  
        After polyacrylamide gels were run, the gels were stained with coomassie brilliant 
blue stain (1g coomassie blue R250, 225ml methanol, 225ml acetic acid and 100ml 
distilled water) for 15 min and de-stained with de-staining solution (400 ml D.W, 50ml 
methanol and 50ml acetic acid). 
  
2.6. Western Blot Technique (Protein Immunoblotting): 
        Analysis by western blot was done according to Harry Towbin, 1979. (Towbin, 
Staehelin et al. 1979) This technique involves transfer of proteins from the polyacrylamide 
gel onto nitrocellulose membrane (Whatman, USA). The gel was equilibrated in 1X 
transfer buffer (14g glycine, 3g tris-base, 100ml methanol, 900ml double distilled water) 
for 1 hour on 100V. The proteins were transferred from gel to nitrocellulose membrane 
(Whatman, USA). After transfer, the membrane was cut into strips and blocked with 
blocking buffer (100ml phosphate buffer saline-Tween-20 (PBS-T) and 5ml Fetal calf 
serum (FCS)) for 30 min at room temperature (RT). Strips then were incubated for 2 hours 
at RT with shaking on shaker with diluted 1:100 and 1:200 Toxoplasma gondii high 
antibody titer pooled sera. Unbound antibodies were washed 3 times for 5 min with 3ml 
PBS-T. After that; secondary antibodies (protein A–HRP) diluted in PBS-T (1:6,000) for 1 
hour with shaking at RT. Excess secondary antibodies were washed off 3 times with PBS-
T. Bound antibodies were detected with DAB substrate (10mg DAB, H2O2, 15ml 50Mm 
Tis-Hcl). Strips were incubated for 15-30 min at RT until band color was observed. Also 
bound antibodies were detected with Enhanced Chemiluminescence (ECL) and according 
to the manufacturer instructions  (ThermoFisher Scientific, USA). 
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2.7. Ponceou-S Stainning: 
        After transfer, the membrane was submerged in Ponceou-S stain for two min. 
Ponceou-S solution (0.1% Ponceou-S, 50% glacial acetic acid in aqueous solution) which 
can be reused.  
 
2.8. Phage Display Peptide Library: 
      The Ph.D.
TM
 Phage Display Library Kit # E8110S (New England Biolabs, Ipswich, 
MA, USA) was used according to the manufacture recommendation with some alterations 
as following: 
 Lauria broth (LB) Media: LB media was prepared by dissolving 10g peptone, 5g 
yeast extract and 5g NaCl in 1L double distilled water, then autoclaved and stored 
at 4˚C until used. 
 LB Plates: 35g LB Agar (DifcoTMLB Agar, Lennox) was dissolved in 1L double 
distilled water, autoclaved for 15 minutes and then poured into petri-dishes. Plates 
finally were stored inverted at 4˚C until used. 
 LB Top Agar: per 250ml: 1.75g yeast extract, 2.5g Nacl and 2.5g peptone. Double 
distilled water then was added up to 230ml and the solution was dissolved. After 
that, 1.8g agar was added, autoclaved and stored at 4˚C until used. The Top agar 
was melted in microwave and equilibrated at 50˚C before use. 
 Bacteria: E. coli ER2738 host strain was used. 5ml LB Broth was inoculated with  
E. coli ER2738 bacteria and incubated at 37˚C for overnight with shaking. 
 IPTG\ X-gal: 1M IPTG (Isopropyl-Beta-D-thiogalactoside) was prepared (2.3g 
IPTG was dissolved with 10ml D.D.H2O). X-gal (5-Bromo-4-chloro-3-indolyl-
beta-D-galactoside) also was prepared (0.2g X-gal was dissolved in 10ml DMSO 
(Dimethyl sulfoxide). X-gal was stored at -20˚C in the dark. 
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 TBST (Tris-bufferd saline and Tween 20): To 500ml TBST, (25ml Tris 7.5, 
1.5ml 5M NaCl, 250 μl Tween-20 and 500ml D.D.H2O. 
2.8.1. Surface Panning using anti-Toxoplasma reactive pool sera: 
2.8.1.1. Binding of reactive phage epitopes: 
         A solution of the pooled sera in 0.1M Sodium bi-carbonate (NaHCO3) (1.05g 
NaHCO3 dissolved in 100ml D.H2O) was prepared. 100μl of this solution was added to 
each well of 96-well microtiter plate or 500μl of this solution was added to each well of 
24-well plate. To coat plate with pooled sera, the plates were incubated overnight at 4˚C. In 
the second day; the coating solution from each plate was firmly slapped face down onto a 
clear paper towel. Next, each well of plate was filled with blocking buffer (100ml TBST 
and 5ml FCS) and incubated for one hour. After that, the blocking buffer was discarded 
and each plate was washed 3 times with TBST. M13 phage vector\library then was added 
onto each plate after the dilution with TBST was done and incubated for one hour at room 
temperature. After that, nonbinding phage was discarded by pouring off and slapping plate 
face down onto a clean tissue paper. Each plate was washed 10 times with TBST. Bound 
phage finally was eluted with glycine elution buffer (0.75g glycine was dissolved with 
50ml D.D.H2O) and the elution buffer was rocked gently for no more than 10-20 minutes. 
The eluted phage was amplified as described below. 
 
2.8.1.2. M13 Bacteriophage Amplification: 
         The eluted phage was amplified by adding into 5ml ER2738 culture (early-log/ 5ml 
Lb broth and 50μl bacteria) and incubated with vigorous shaking at 37˚C for overnight. 
After incubation period, the culture was transferred to centrifuge tube and centrifuged for 
10 minutes at 14,000rpm. Next, 1ml supernatant was transferred to a new fresh tube and 
200μl of 20%PEG/2.5M NaCl was added. Phage was allowed to precipitate for overnight 
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at 4˚C. The PEG precipitation then was spun at 14,000 rpm at 4˚C for 10 minutes and the 
supernatant was discarded. The phage pellet was suspended with 1 ml TBS, 100μl of 20% 
PEG/ 2.5M NaCl was added. Then it was incubated at 4˚C for 1 hour. After incubation 
period, the tube was centrifuged at 14,000rpm for 10 min and the supernatant was 
discarded and 100μl TBS was added onto the phage pellet; which at this step the amplified 
phage was obtained (first round of panning was carried out). The Amplified  phage was 
used in a second M13 phage surface binding/screening, and the amplified phage of the 
second screening round was used in a third round of screening. The M13 phage that was 
produced from the third screening round (surface binding) was amplified and named as the 
final amplified phage. This bio-panning process was done at least five times and in each 
time the third amplified phage was collected. The resulted amplified phage was tittered on 
LB/IPTG/X-gal plates. (section 2.8.1.3.) 
 
2.8.1.3. M13 Bacteriophage Titration: 
       The number of plaques was linearly increased with added phage obtained from phage 
Display library Kit) when the bacterial cells were in excess (multiplicity of infection 
(MOI) was much less than 1). 5ml broth was inoculated with ER2738 from a freshly grown 
culture and incubated for overnight at 37
o
C until had reached mid-log phase, (reach OD600 
of about 0.5). In the next day,  top agar was melted in microwave and dispensed into 5ml 
in 15ml sterile culture tubes. Each tube was maintained at 50
o
C. Serial dilutions of M13 
Bacteriophage in LB (10
3
 to 10
16
-fold) were prepared in 1ml LB final volume. After the 
ER2738 culture had reached mid-log phase, 200μl were dispensed into microfuge tubes, 
one for each phage dilution. 200μl ER2738 bacteria and 10μl phage then were added into 
top agar. Tubes were briefly and immediately poured onto a pre-warmed LB/IPTG/X-gal 
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plate. Plates were then gently rotated to spread top agar evenly. Plates were incubated 
overnight at 37°C.   
2.8.2. M13 phage plaque assay: 
       After performing phage titration test, it was found that the phage titer is up to 10
15
;  
this titer produced about 100 separated plaques per plate. The final amplified M13 phage 
was grown on 25 different plates in a dilution of 10
12
 (pfu/ml), the obtained plaques from 
each plate were transferred into nitrocellulose membrane (Whatman, USA) and then 
screened to their reactivity against anti-Toxoplasma gondii pooled sera as described below.  
 
2.8.3. Plaque lifts into nitrocellulose membranes: 
        Before the plaques were lifted onto nitrocellulose membrane, the prepared 
M13 phage plates were kept for overnight at 4°C to prevent the top agar from sticking to 
the nitrocellulose membrane and increase titer\plaques. To each LB agar/IPTG/X-gal plate 
containing plaques a nitrocellulose membrane was placed over the plaques for 5 min to 
allow the transfer of the phage plaques to the membrane. A prick through the membrane 
and agar was done by a pen for orientation. The plates then were incubated for 30 min at 
37°C and then incubated for 1 hour at 4°C. The membranes next were removed from the 
plates and kept at room temperature for overnight to dry and to fix the phage protein to the 
membrane. The dried membranes were submerged in phosphate buffer saline for few 
minutes and then blocked with 5% FCS in PBS with Tween-20 for 30 min. Finally, 
screened by anti-Toxoplasma gondii high antibody titer positive human sera as mentioned 
in Western blotting.  (See 2.6.)  
2.8.4. Selected Plaques screening by anti-Toxoplasma Pooled Sera: 
          All selected plaques that showed reactivity with Toxoplasma gondii pool sera (High 
Antibody titer) were picked by sterile micropipette tips and used to inoculate 1.5ml tubes 
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containing 300μl LB medium. All tubes were kept at 4°C. Reactive plaques with high 
Antibody titer human pooled sera (Selected plaques) were amplified as mentioned in phage 
amplification (see 2.8.1.2) to suspended and obtained precipitate phage to perform Dot-
ELISA (Phage Dot-Blot Assay) and phage ELISA binding assay. The phage dot-blot assay 
(Dot-ELISA) and phage ELISA binding assay were done as described below.  
 
2.9. Dot-ELISA (Phage Dot-Blot Assay): 
          A total of selected M13 phage clones (amplified reactive plaques) suspended with 
TBS were prepared and concentrated (100μl, 50μl and10μl) and (30μl and 10μl). 
Nitrocellulose membrane were soaked in 1x PBS and placed on dot blotter apparatus (Bio-
rad, USA) which was connected to vaccume pump. These selected M13 peptide phage 
clones were blotted onto the nitrocellulose membrane and allowed to air-dry for overnight 
at room temperature, the membrane then was blocked with 5% FCS and 100ml PBST for 
30 min at room temperature (RT). Membrane was incubated for 2 hours at RT with 
shaking in diluted 1:500 Toxoplasma gondii high antibody titer pooled sera. Unbound 
antibodies were washed 3 times for 5 minutes with PBS-T. Secondary antibodies (protein 
A–HRP) diluted in PBS-T (1:6,000) was added for 1 hour at RT. Excess secondary 
antibodies were washed off 3 times with PBS-T. Bound antibodies were detected with ECL 
(Film-developer). (Sastry, Tuteja et al. 2003)  
 
2.10. Enzyme Linked Immunosorbent Assay (ELISA):  
         Two microtiter plates were coated with isolate and concentrated phage (amplified 
phage) in duplicates, they incubated for 24 hours at 4˚C and then blocked (100μl/well) with 
100ml PBS-T and 5%FCS and incubated for 40 minutes at room temperature and washed 3 
times with PBS-T. Next, 100μl of 1:200 serially diluted pooled sera were added as first 
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Abs and incubated for 2 hours and washed 3 times with PBS-T. 100μl diluted protein A 
(1:6,000) was added as second antibodies and incubated for 1 hour at room temperature 
then washed 3 times with PBS-T. 200μl of the substrate solution (40mg of the O-
phenyldiamine (OPD), 30ml of 0.1M tri-sodium citrate buffer (pH5)) and 30μl of H2O2) 
was added and incubated for 30 min at room temperature. Yellow color development 
finally was measured at 490nm using ELISA auto-reader. Amplified phages that showed 
high antibody titer were coated again into 96-well microtiter plates. Five amplified phages 
were chosen to be tested if there are reactivity between them and sera of Toxoplasma 
gondii infected individuals. (Jalallou, Bandepour et al. 2010) 
 
2.11. Polymerase Chain Reaction (PCR): 
         All selected phage clones were detected by phage dot-blot (Dot-ELISA). 
These selected clones were identified by amplification reactive phage gene by Polymerase 
Chain Reaction (PCR). PCR analysis was done by using primers against a portion of the 
M13 Bacteriophage gene. The Ph Rev2 primer and Ph Direct2 primer (Sigma Chemical 
Co.) were used. PCR analysis firstly was carried out for 27 samples (including the negative 
controls), a master mix tube was prepared as followed: 540µl double distilled water, 30µl 
of 20 pmoles of ph Direct2 primer and 30 ph Rev2 primer, then it was  mixed well and 
20µl was dispensed in each Ready Mix PCR tubes (Syntezza, Jerusalem) followed by the 
addition of 5µl from each extracted DNA sample. The used thermal profile in thermo-
cycler involving 5 min at 95°C to initial denaturation, followed by 35 cycles each of 30 
second at 95°C to complete denaturation, 30 sec at 55°C TM (depends on the used 
primers) to perform annealing, followed by extension step (elongation) that involved 1 min 
at 72°C, and a final elongation step at 72°C for 10 min. PCR analysis of other samples with 
the same procedure was performed with all 27 samples. (Bourdin, Busse et al. 2014) 
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2.12. Agarose Gel Electrophoreses: 
          PCR products were run on a 1.5% agarose gel (1.5g agarose, 100ml 50X TAE and 
10µl Ethidium bromide in 50X TAE electrophoresis running buffer (242g Tris base, 
57.1ml glacial acetic acid and 100ml 0.5M EDTA (Ph8.0)). The Gene Ruler 50bp DNA 
ladder (Thermo Scientific, # SM0371) was used for sizing PCR amplified products. 
(Ramberg 2006) 
 
2.13. DNA Purification: 
 PCR products were purified by GeneJET PCR purification Kit (Thermo Scentific, 
USA), according to manufacturer's instructions with some modifications. The DNA 
purification steps were done as following: The remaining quantity of PCR product for each 
sample was added into eppendorf tube; 100µl of sterile D.D.H2O then was added. Next, 
200µl of binding buffer was added in each tube and centrifuged for 60 sec to discard flow- 
through. 700µl wash buffer (ethanol) was added to the GeneJET purification column for 
each sample. Then each tube was centrifuged for 3 min and the flow-through was 
discarded. GeneJET purification column was centrifuged again to remove any residual 
wash buffer. The GeneJET purification column next was transferred into 1.5ml 
microcentrifuge tube and 30µl D.D.H2O was added to concentrate DNA. Then, all tubes 
were incubated at RT for 2 min and then centrifuged for 60 sec. Then the purified DNA 
was stored at -20°C; which all samples were ready for sequencing. 
 
2.14. DNA sequencing: 
          Purified PCR products were sequenced according to dye terminator method, using 
Automated DNA Sequencer machine (AB477). The primers that used to DNA 
amplification were used there, for each PCR product primer was used in DNA sequences 
acquaint. 
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Part 3: Results. 
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3.1. Modified Agglutination Test (MAT): 
        The collected sera samples from pregnant women were screened for the presence of 
Toxoplasma gondii infection. The reactivity of these collected sera to Toxoplasma gondii 
and evaluation of the presence of IgG antibody against Toxoplasma parasite were 
determined based on serological examination for collected sera by simple Modified 
Agglutination Test (MAT). This MAT test depends on agglutination of formalin fixed T. 
gondii tachyzoite parasite cells. The design of Toxoplasma gondii agglutination test and 
representative results of Toxoplasma MAT test in microtiter plate are shown in figures 
3.1.1 and 3.1.2. 
 The antibody titers for the different tested sera samples were identified starting 
from 1:5 dilution up to 1:320 serum dilution (As shown in Table 3.1.1). The total number 
of collected sera samples was 204, from which a total of 116 samples gave positive results. 
The percentage of the tested samples that gave antibody titer of 1:20 and above was 16% 
from the total, while those that gave 1:5 and 1:10 antibody titer by MAT test was 22% and 
19%, respectively (Figure 3.1.3). All positive sera that gave 1:20 antibody titer in MAT 
test were collected in one pool and was named as  (high antibody titer positive human 
sera), a total of 45ml was pooled.  
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Figure 3.1.1: Plate design of Toxoplasma gondii agglutination test. A1-A6: represents 
positive controls. B1-B6 up to HI-H6 and A7-A12 up to H7-H12: represent the collected 
samples. A total of 15 samples were tested in this microtiter plate. 
 
 
 
Figure 3.1.2: A representative results of Toxoplasma agglutination test. 
Representing detection of anti-Toxoplasma gondii antibodies for the collected 
sera samples. The collected sera samples were diluted to (1:10, 1:20, 1:40, 
1:80, 1:160 and 1:320). 
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Table 3.1.1: Antibody titers of the different tested sera samples based on 
MAT test against formalin fixed tachyzoite Toxoplasma gondii parasite. 
 
Antibody Titer Number  of 
positive 
samples 
Percentage of 
antibody titer 
1:5 
1:10 
1:20 
1:40 
1:80 
1:160 
1:320 
45 
39 
12 
12 
3 
2 
3 
22% 
19% 
6% 
6% 
1.5% 
1 % 
1.5% 
Total number of 
positives  
116 57% 
Total number of 
negatives 
88 43% 
Total number of tested 204 100% 
 
 
Figure 3.1.3: Pie chart that summarizing the proportions of the different obtained human 
positive sera and their antibody titers based on MAT test. 
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3.2. SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blot analysis:  
3.2.1. SDS-PAGE: 
     Toxoplasma gondii crude antigen extract and amplified phage peptides (resulted from 
the third round of phage panning) were analyzed by SDS-PAGE and Western blotting 
techniques. From the prepared extracts; 15µl total volume were run on SDS-PAGE. Four 
different gels were prepared each containing parasite crude extracts, amplified phage 
peptides and MW marker. Two of the gels were stained with Commasie brilliant blue stain 
(data shown only for one gel; Figure 3.2.1). The SDS-PAGE analysis of the Toxoplasma 
gondii crude antigen extract shows a major  multi-band that had different molecular weight 
sizes ranging from 70-100 kDa. The phage peptides showed a major band that had a 
molecular weight of 60 kDa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.1: Commassie Brillient Blue-Stain of 10% SDS-PAGE gel. A: represents amplified 
phage proteins. B: represents crude extract protein banding pattern. M:  Molecular weight 
marker.  
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3.2.2. Western blot analysis: 
        The reactivity of Toxoplasma gondii crude antigen extracts with high antibody titer 
positive human pooled sera collected from Toxoplasma gondii infected pregnant women 
was determined by immuno-blot analysis. The reactivity of the amplified phage (produced 
from third-round-panning) against high antibody titer positive human pooled sera is shown 
in figure 3.2.2 and 3.2.3. Immunoblotting analysis revealed one band at molecular weight 
of 50 kDa using the phage extract and more than one band upon the use of Toxoplasma 
crude antigen extract; with a major band that had a molecular weight of 50 kDa and other 
minor bands of about 100 kDa (Figure 3.2.2). Similar results were obtained even if more 
sensitive analysis by the aid of enhanced chemo-luminescence (ECL) assay (As shown in 
figure 3.2.3). The reactive antibody with Toxoplasma crude antigen extract was IgG, since 
the anti-human IgG-HRP and protein-A-HRP were used as secondary. 
 
 
 
 
 
                                             
 
 
 
Figure 3.2.2: Western-blot analysis for Toxoplasma gondii crude antigen extract and 
amplified phage using OPD substrate. Representing the reactivity of Toxoplasma gondii crude 
antigen extracts with high antibody titer positive human pooled sera. Protein A-HRP was used as 
secondary antibody. Strip no.1 represents reactivity of amplified phage with high antibody 
pooled sera. Lane no.2 represents the reactivity of crude antigen extract. MW: molecular weight 
marker. 
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3.3. Screening of M13 random phage display library: 
      The M13 phage library titer indicated by the phage library manufacturer (New England 
Biolabs, Ipswich, MA, USA), was estimated to be 10
13
 plaque forming units (pfu)/ml. The 
titer of the phage library decreases along storage time, for this reason and for obtaining a 
workable number of plaques (separated plaques) in each plate; the phage library was 
titrated using different dilutions of phage library starting from 10
3
 down to 10
16
. Each 
dilution was used to infect 200µl of freshly grown E. coli bacteria followed by plating on 
LB agar plates that include IPTG/X-gal as described in materials and methods. After 
performing phage titration test, it was found that the phage titer was up to 10
15
(pfu)/ml.  
3.3.1. M13 phage screening and selection using anti-Toxoplasma gondii pooled 
sera: 
 The final amplified M13 phage was grown on 25 different plates in a dilution of 
10
12
 (pfu/ml), the obtained plaques from each plate were transferred into NC membrane 
Figure 3.2.3: Western-blot analysis of Toxoplasma gondii crude antigen extract 
and amplified phage detected by highly sensitive enhanced chemo-luminescence 
(ECL) assay. Representing the reactivity of Toxoplasma gondii crude antigen extracts 
with high antibody titer positive human pooled sera collected from pregnant women. 
Protein A-HRP was used as secondary antibody. Strip no.A: represents reactivity of 
amplified phage with high antibody pooled sera. Strip no.B: represents the reactivity 
of crude antigen extract. MW: molecular weight marker. 
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and then screened to their reactivity against anti-Toxoplasma gondii pooled sera. Plaques 
that were lift on the NC membrane from each plate was screened by 1:500 diluted anti-
Toxoplasma gondii pooled sera as first antibody and 1:5000 diluted protein A-HRP or anti-
human IgG-HRP as a second antibody (Figure 3.3.1). The highly reactive plaques (plaques 
that gave strong color signals) were transferred and incubated in 300μl LB media for 
further analysis. The total number of the obtained M13 reactive phages was 329 plaques 
from a total of 25 plates (Table 3.3.1), that are estimated to have at least 5000 plaques 
(assuming in each plate there are only 200 plaques). From the total number of the obtained 
M13 reactive phages (329 plaques); 138 reactive plaques were picked up and used for 
further analysis in this study. 
 
Figure 3.3.1: Plaques Selection and Screening with Toxoplasma high antibody titer 
pooled sera by biopanning process. Panel A1: represents separated plaques when 
amplified phage tittered on LB agar/IPTG/X-gal plate and Panel A2: represents plate with 
nitrocellulose membrane (alignment of strong color signals with separated plaques after 
reactivity between plaques and Toxoplasma high antibody titer pooled sera). 
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Table 3.3.1: Summary for the number of obtained plaques from 25 different plates and that 
were reactive with anti-Toxoplasma high antibody titer pooled sera. 
Plates number Number of reactive plaques Total 
1 25  
 
 
 
 
 
 
 
 
329 
2 29 
3 19 
4 2 
5 30 
6 24 
7 5 
8 18 
9 3 
10 15 
11 22 
12 10 
13 1 
14 4 
15 26 
16 9 
17 14 
18 2 
19 3 
20 16 
21 8 
22 22 
23 3 
24 12 
25 7 
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3.4. Proving reactivity of isolated M13 phages by Dot-ELISA (Phage Dot-
Blot Assay): 
         Before investing in M13 phage epitopes identification by DNA sequencing; the 
reactivity of selected M13 phage clones with anti-Toxoplasma gondii high antibody titer 
pooled sera were confirmed by Phage Dot-Blot Assay. The first of two NC membrane 
received (100μl, 50μl and10μl of different selected amplified phages) and the second NC 
membrane received (30μl and 10μl of different selected amplified phages). The spotted 
phages were in both membranes were reacted against diluted (1:500) anti-Toxoplasma 
gondii high antibody titer pooled sera,  protein A–HRP was used in a dilution of 1:6000 as 
secondary antibody. The dot-ELISA results showed reactivity with most selected and 
amplified M13 phage. Dot-Blot Assay revealed and standardized for the confirmation of  
reactivity selected M13 phage clones with Toxoplasma gondii high antibody titer pooled 
sera. (figure 3.4.1 and 3.4.2). 
 
 
 
 
Figure 3.4.1: Screening of selected amplified M13 phage clones by dot-ELISA. 
Selected M13 phage clones suspended in TBS and blotted (100μl, 50μl and10μl) onto 
the nitrocellulose membrane. (1-23 are different selected phages reacted with 
Toxoplasma gondii high antibody titer pooled sera). 
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3.5. Phage ELISA Binding Assay: 
 
3.5. Phage / ELISA immunological reactivity assay: 
Antibody titers of pooled sera reacted with amplified phages (reactive phages) were 
determined by ELISA assay using two plates with a difference in the used second antibody 
anti-human-IgG-HRP was used in the first plate and protein-A-HRP was used in the 
second plate. The results of this interaction showed high ELISA readings indicating high 
reactivity between isolate amplified phages and the pool sera. Based on this assay, the 
phage groups that produced the highest antibody titers were used to coat new ELISA 
plates. Five different groups were used to coat five different ELISA plates.  These coated 
plates were examined for their reactivity with collected sera of Toxoplasma gondii infected 
individuals with other negative control sera. The results indicate that, the five selected 
phage groups used in this ELISA assay; showed consistency and high antibody titer in 
terms of their reactivity against the examined phages. (As shown in figure 3.5.1) 
Figure 3.4.2: Screening of selected amplified M13 phage clones by dot-ELISA. 
Selected M13 phage clones suspended in TBS and blotted (30μl and 10μl) onto the 
nitrocellulose membrane. (1-23 are different selected phages reacted with Toxoplasma 
gondii high antibody titer pooled sera). 
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Figure 3.5.1: Phage ELISA Binding Assay for different sera of Toxoplasma gondii infected 
individuals reacted with different five amplified phages. I, II, III, IV and V: Represent ELISA 
immunoassay to different isolate concentrated phages and different sera of Toxoplasma gondii 
infected individuals. Protein A used as secondary antibody. B: is a Blank. No.5: is a positive 
control. No. 6: is pooled sera. No. 12&13: are Negative controls. No. 1, 2, 3, 4, 7, 8, 9, 10, 11, 14, 
15, 16, 17, 18, 19, 20, 21, 22 and 23: are different sera of Toxoplasma gondii infected individuals 
defined as high antibody titer.  
V 
III IV 
I II 
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3.6. M13 phage epitopes identification: 
From a total of 138 selected M13 phage plaques that were chosen after three 
screening cycles with Toxoplasma gondii pooled sera, 24 different plaques were selected 
for sequence analysis and the Peptides coding sequences of the 24 different clones 
identified by high antibody titer Toxoplasma gondii pooled sera were obtained (sequences 
are shown in appendix A). The 24 plaques were selected based on their strong signals 
obtained after reactivity of the bound protein-A-HRP to the human antibodies from 
Toxoplasma gondii infected pooled sera that succeeded to identify the different M13 phage 
plaques. These plaques represent M13 phage epitopes that bind to antibodies against 
Toxoplasma gondii. Searching the GenBank; there was no DNA similarity or amino acid 
similarity between the obtained sequences and Toxoplasma gondii parasite DNA genomic 
sequences. But the sequences of the inserted clones which represent the selected M13 
phages showed similarity to some related  protozoan parasites such as Plasmodium 
knowlesi and Plasmodium fragile. (as shown in 3.6.3.1) 
 
3.6.1. DNA amplification of the fused peptide/pIII M13 phage from the selected 
clones: 
          To identify selected plaques through DNA amplification of the fused peptide of pIII 
M13 phage, its known insertion site of the random peptides in the pIII M13 phage gene to 
form a sequence of random peptide library pIII fusion peptides. Based on this information 
of M13 phage library construction (New England Biolabs, Ipswich, MA, USA) and on the 
DNA sequence information of the pIII gene; a pair of primers were designed to enable a 
specific amplification of the fusion peptide (Figure 3.6.1). PCR primers were designed 
based on the information that is provided in the manufacturer company of the M13 phage 
library. At this stage; DNA was amplified using two primers that are flanking the peptide 
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region and amplifying a DNA segment about of 250bp (Table 3.6.1). Based on previous 
studies that showed it amplification of the inserted peptides by using Ph Rev2 and Ph 
Direct 2 primers that shown in table 3.6.1 and figure 3.6.1. 
Ph Direct2 and Ph Rev2 primers were used in PCR amplification of the fused 
DNA, the Ph F and Ph Rev2 primers also were used in a combination in DNA 
amplification. But Ph Direct2 and Ph Rev2 primers revealed success in amplification of 
DNA segments to the selected clones more than Ph F and Ph Rev2 primers due to the Ph 
Direct2 and Ph Rev2 primers gave sharp bands compared to Ph F and Ph Rev2 primers. 
These PCR primer combinations (Ph Direct2 and Ph Rev2) were able to amplify about of 
250bp DNA segment that include the inserted peptide and the flanking region from the pIII 
gene. PCR system was able to amplify the DNA segment from all the 45 selected clones. 
(As shown in figures 3.6.3 and 3.6.4) 
 
 
 
 
 
 
 
Ph Direct2 
Ph Rev2 
Figure 3.6.1: DNA and amino acid sequence information of the pIII-peptide fusion in 
M13 phage. Demonstrating the location of two primers that were used in DNA segment 
amplification; Ph Direct2 : at 5’end and Ph Rev2: at 3’end. Direction of clone fusion: 
5’end-3’end. 
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Table 3.6.1: Primers names and their DNA sequence; that were used in amplifying the 
pIII-peptide fusion DNA fragment from M13 phage.  
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6.2. DNA sequencing of the fused peptides pIII gene: 
Twenty four clones were chosen from among 45 selected clones based on a third 
screening cycle with Toxoplasma gondii high antibody titer pooled sera for further analysis 
Phage 
primers 
DNA sequence Size of the amplified DNA band 
Ph F ATT CAC CTC GAA AGC AAG CT Using PhF and PhRev2 
About (220bp) 
Ph Direct2 
TTA TTC GCA ATT CCT TTA GTG 
Using PhDirect2 and PhRev2 
(250bp) 
Ph Rev2 CC CTC ATA GTT AGC GTA ACG  
 
ggagcctttt ttttggagat tttcaacgtg aaaaaattat
tattcgcaat tcctttagtg gtacctttct attctcactc
T         Site of inserted peptide 
gctacttcg catctgcatg ttcggttgcc gtcgaagggt
ggaggttcgg ccgaaactgt tgaaagttgt ttagcaaaat
cccatacaga aaattcattt actaacgtct ggaaagacga
caaaacttta gatcgttacg ctaactatga ggga
5’-
- 3’
Figure 3.6.2: DNA sequence of larger segment of the pIII M13 gene with the site of the 
inserted sequence. By the aid of this sequence of  PIII M13 gene direct primer (Ph Direct2) 
near the 5’-end, and a reverse primer (Ph Rev2) near the 3’-end were designed to enable 
larger DNA fragment amplification.  
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and later for peptide identification. Namely these clones were (Ph1, Ph5, Ph7, Ph8, Ph10, 
Ph13, Ph14, Ph18, Ph19, Ph20 (old), Ph23 (old), Ph24 (old), Ph21, Ph22, Ph23, Ph24, 
Ph25, Ph26, Ph27, Ph28, Ph29, Ph30, Ph31and Ph32). Amplicons of indicated clones were  
purified and sent for DNA sequencing. After receiving the DNA sequences; it was shown 
that clones Ph28, Ph21, Ph25, Ph26 and Ph27 were not successfully sequenced. Analysis 
of DNA sequences was performed for the remaining 19 clones.  
 
 
    
 
 
 
 
Figure 3.6.3: Agarose gel electrophoresis analysis of the amplified PCR products.  Ph 
Direct2 and Ph Rev2 primers targeting the fused peptide in pIII M13 phage gene in the 25 
different selected clones. Sample no.1 is ph1, no.5 is ph5, no.7 is ph7, no.8 is ph8, no.10 is ph10, 
no13 is ph13, no.14 is ph 14, no.18 is Ph18, no.19 is Ph19, no.20 is Ph20 old, no.23 is Ph23 old 
and no.24 is Ph24 old. –ve is a Negative control. M: Molecular weight marker. 
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3.6.3. Bioinformatics and DNA sequence analysis: 
Bioinformatics was used for the similarity searching to the 19 remaining putative 
peptide sequences through using BLAST online service provided through the PubMed /US 
National Institute of Health (http://www.ncbi.nlm.nih.gov/pubmed/).  
Firstly, by the aid of BLAST program; the DNA sequence alignment of the 12 
amino acid coding region including the flanking regions of the pIII gene of M13 phage was 
obtained. The sequences of 19 remaining putative peptides represent the selected M13 
phages that showed cross-reactivity with anti-Toxoplasma pooled sera, 5’-end represented 
histidin and serine amino acids and those the 3’-end represented three glycine molecules. 
(As shown in figure 3.6.5) 
From the 19 examined peptide DNA sequences, no clones showed similarity to 
Toxoplasma gondii parasite DNA genomic sequences. But the sequences of the inserted 
clones which represent the selected M13 phages that showed cross-reactivity with anti-
Figure 3.6.4: Agarose gel electrophoresis analysis of the amplified PCR products. Ph 
Direct2 and Ph Rev2 primers were targeting the fused peptide in pIII M13 phage gene in the 
26-45 different selected clones. M: Molecular weight marker. Samples from no.26 to no.33 
are ph21 to ph28. Samples no.36 and 37 are ph29 and ph30. Samples from no.41 and 42 are 
ph31 and ph32. 
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Toxoplasma pooled sera; which the sequences represent the selected M13 phages related to 
protozoan parasites such as Plasmodium knowlesi and Plasmodium fragile. (as shown in 
section 3.6.3.1) 
The DNA sequence similarity data analysis for peptides by BLAST analysis 
showed a 100% similarity with Blastocystis hominis and Echinostoma caproni. Also, and 
in another region of the peptide sequence that represents 96% similarity with Spirometra 
erinaceieuropaei. Similarity data analysis for peptides also showed 92% similarity with 
Plasmodium fragile, Spirometra erinaceieuropaei, Enterobius vermicularis and 
Diphyllobothrium latum. Some of these parasites are protozoan parasites and are closely 
related to Toxoplasma family (Sarcocystidae). (as shown in 3.6.3.1)  
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   Figure 3.6.5: DNA sequence alignment of the 12 amino acid coding region including the flanking regions of the pIII gene of M13 phage. 
The sequences represents the selected M13 phages that showed cross-reactivity with anti-Toxoplasma pooled sera, At 5-end represents histidin 
and serine amino acids and those at the 3’-end represents three glycine molecules.
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3.6.3.1. The DNA sequance similarity data analysis for peptides of clones: 
1- Plasmodium knowlesi strain H chromosome 12, complete genome  
         Sequence ID: AM910994.1   Identities:27/30(90%) 
 
Query  2        TTCAGTCGCTTCCGTTTAAT-GCTTCTGTT  30 
                ||||| |||||||||||| | ||||||||| 
Sbjct  2876597  TTCAGGCGCTTCCGTTTAGTCGCTTCTGTT  2876626 
 
 
2- Plasmodium fragile hypothetical protein partial mRNA  
       Sequence ID: XM_012480995.1  Identities: 24/26(92%) 
 
Query  4     CTTAATTCTGTTCATCATCAGACTCG  29 
             ||| |||||| ||||||||||||||| 
Sbjct  2965  CTTCATTCTGCTCATCATCAGACTCG  2940 
 
 
3- Chistosoma margrebowiei  
       ID: LL879171.1   Identities: 29/33(88%) 
 
Query  2      ATTGGTCGGTGATTACGTCGTACTGTTTTGAGG  34 
              |||||| |||||||  || |||||||||||||| 
Sbjct  16430  ATTGGTTGGTGATTT-GTGGTACTGTTTTGAGG  16461 
 
 
4- Spirometra erinaceieuropaei  
        ID: LN295640.1   Identities: 25/28(89%) 
 
Query  8    CGGTGATTACGTCGTACTGTTTTGAGGT  35 
            || |||||| || ||||||||||||||| 
Sbjct  992  CGCTGATTAAGTGGTACTGTTTTGAGGT  965 
 
 
5- Spirometra erinaceieuropaei  
       LN070735.1         Identities: 23/25(92%) 
 
Query  11   TGATTACGTCGTACTGTTTTGAGGT  35 
            |||||| || ||||||||||||||| 
Sbjct  721  TGATTAAGTGGTACTGTTTTGAGGT  697 
 
 
6- Enterobius vermicularis  
       ID: LM416346.1      Identities 23/25(92%) 
 
Query  6     GTCGGTGATTACGTCGTACTGTTTT  30 
             |||||||||||| | |||||||||| 
Sbjct  6900  GTCGGTGATTACATTGTACTGTTTT  6924 
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7- Diphyllobothrium latum  
      ID: LL596793.1    Identities: 23/25(92%) 
 
Query  2     ATTGGTCGGTGATTACGTCGTACTG  26 
             ||||||||||||| ||||| ||||| 
Sbjct  3669  ATTGGTCGGTGATCACGTCTTACTG  3645 
 
 
8- Echinostoma caproni  
      ID: LL233882.1    Identities: 20/20(100%) 
 
Query  13     ATTACGTCGTACTGTTTTGA  32 
              |||||||||||||||||||| 
Sbjct  19322  ATTACGTCGTACTGTTTTGA  19341 
 
 
9- Blastocystis hominis  
      XM_013043335.1    Identities: 20/20(100%) 
  
Query  16   TTGTTGCTTCATCAGAAGAA  35 
            |||||||||||||||||||| 
Sbjct  158  TTGTTGCTTCATCAGAAGAA  177 
 
 
10- Spirometra erinaceieuropaei  
 Identities: 22/23(96%) 
 
Query  3     TGATGTGGATCGTTTGTTGCTTC  25 
             |||||||||||||||||| |||| 
Sbjct  4403  TGATGTGGATCGTTTGTTCCTTC  4425 
 
 
11- Echinostoma caproni  
         ID: LL233138.1   Identities: 25/28(89%) 
 
Query  7       GTGGATCGTTTGTTGCTTCATCAGAAGA  34 
               || |||||  |||||||||||||||||| 
Sbjct  129654  GTTGATCGGGTGTTGCTTCATCAGAAGA  129681 
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Part 4: Discussion and Conclusion. 
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Discussion: 
       The present study was performed to develop a suitable Toxoplasma immunological test 
based on identification of immunoreactive peptides of M13 Bacteriophage and to provide a 
continuous source of Toxoplasma antigenic material in sufficient quantities to be used in an 
ELISA technique or to be bound on synthetic latex or sheep red blood cells in order to 
perform agglutination test. This study was also performed due to the public health concern 
about toxoplasmosis. The disease has been reported in almost all the world, that affect up to 
one third of the human population in the world including the Mediterranean regions and 
neighboring countries; Arabian Gulf countries, Turkish, Beirut, Iran and Jordan. (Khammari, 
Saghrouni et al. 2013; Jones, Wilson et al. 2001; Montoya, Bennett et al. 2000).  Previous 
studies have identified the prevalence of Toxoplasma gondii in Palestine (Hebron and Gaza 
cities), the studies showed high IgG and IgM antibody titers among pregnant women. (Al-
Hindi and Lubbad 2009; Nijem and Al-Amleh 2009). The seroprevalence of Toxoplasma 
gondii in goats, sheep, chicken and turkeys were determined in Jenin, Tulkarm, Beer Sheva, 
Tel-Aviv and Jerusalem. (Salant et al. 2016; Othman and Al-Zuheir 2014)    
         The study also performed because of some imported commercial IgM test kits for 
toxoplasmosis had problems with specificity, resulting in high rates of false-positive test 
results, and these kits have low specificity and the reported results are misinterpreted  (Jones, 
Wilson et al. 2001; Montoya 2002). False positive IgM antibodies results may obtain if 
individual have Rheumatoid factor (RF) and antinuclear antibodies. (Montoya 2002; 
Abolghasem et al. 2011) 
 Infection caused by Toxoplasma parasite in human is characterized by the appearance of 
anti-Toxoplasma antibodies in the sera of the patients. The disease can be diagnosed in 
human by serological tests that includes the detection of IgM and IgG antibodies, or directly 
by molecular methods. (Paquet et al. 2013; Goldstein, Montoya et al. (2008); Hill and Dubey 
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2002) In our study, MAT was used to determine the antibody titers of the different tested 
serum samples against Toxoplasma gondii crude antigen. The MAT test utilizes formalized 
tachyzoites and it detects only IgG antibodies as mercaptoethanol used in the test destroys 
IgM antibodies. The test has been reported to demonstrate high sensitivity and specificity 
when compared to other serological assays. (Shaapan et al. 2008)  All positive sera that gave 
1:20 antibody titer in MAT test were collected in one pool. The pooling strategy was done, 
since the pool sera provide sufficient amount of anti-Toxoplasma gondii antibodies to carry 
out phage display libraries analysis and western blot at this study. 
The reactive antibody with Toxoplasma crude antigen extract is IgG, since the Anti-
human IgG and protein A (anti-human-HRP) were used as secondary antibodies during 
immunoblotting. Performing western blot technique in this study was important to enable 
planning for the screening of the phage library and to be sure about the reactivity or not of the 
high antibody titer positive human pooled sera collected from Toxoplasma gondii infected 
pregnant women with the different phage displayed epitopes. 
          Phage display is considered as the powerful methodology that includes production and 
screening a large number of random peptides of a specific length (8-20 amino acids) that 
expressed on the surface of phage. (Devlin and Panganiban 1990) In which peptides and 
proteins displaying on the surface of filamentous bacteriophage are the powerful 
methodology for protein identification, according antibodies are react with peptides and 
proteins displaying on the surface of filamentous bacteriophage. (Morozova and Tikunova 
2009) Smith demonstrated that peptides on the surface of M13 bacteriophage can be 
expressed and affinity enrichment method termed "Biopanning" was developed. (Parmley 
and Smith 1988)  
Theoretically, phage titration approach aims to enrich the plate with many plaques of 
the same type, and it is recommended to grow the phages in a titer that gives a lower number 
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of plaques per plate in order to enable easier isolation of independent plaques without any 
overlapping between them. 
Blue-white screening allowing rapid detection of the plaques on the plate. A lawn of 
white-blue plaques on LB\IPTB\Xgal plate were obtained; blue plaques indicated that the  
amplified phages (viable phages) which the blue plaques resulted due to M13 bacteriophage  
carries  lacZ gene, so phage plaques appear blue when plated on media containing IPTG and 
Xgal and blue plaques were picked rather than white plaques since the white plaques 
indicated that the sever contamination with the environmental M13-like phage during phage 
panning and amplification. (Messing Gronenborn et al. 1977)  
After receiving the formations about DNA sequences; it was shown that the clone 
Ph28 was not successfully sequenced may due to mixed PCR amplification products. Ph21, 
Ph25, Ph26 and Ph27 also showed unidentified nucleotides through these sequences; these 
results obtained may due to overlapping between more than one picked reactive plaques or 
clones in these PCR amplified products.  
The results of DNA sequencing showed no similarity of the obtained M13 phage 
epitopes to already known Toxoplasma proteins or sequences in the Gene Bank data base. 
This finding exclude the other obtained reactive peptides (sequenced or not) due to these 
peptides were bound to antibodies from Toxoplasma gondii infected pool sera. Epitopes 
considered as a small sequence of amino acids about 5-6 and these amino acids and have 
ability to form folding patterns also there are two types of epitopes; namely sequential 
epitope that based on sequence and conformational epitope that based on conformation. 
(Flanagan 2011; Huang and Honda 2006) In general most of selected and sequenced peptides 
had no linear sequence identities with any currently known proteins or DNA sequences and 
no complete consensus linear motif in common. This fact may eliminate the role of these 
peptides as sequential epitopes but never as conformational epitopes or as mimitopes that 
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mimic different antigenic proteins of similar amino acid composition, or carbohydrates that 
have similar conformational structure; which different amino acids can give the same of 
conformation of epitopes they can identify the antibodies. (Editorial 2001)    
The sequences of the inserted clones which represent the selected M13 phages that 
showed cross-reactivity with anti-Toxoplasma pooled sera; which the sequences represent the 
selected M13 phages related to and identified as protozoan parasites such as Plasmodium 
knowlesi and Plasmodium fragile. The selected clones had also a cross reactivity with 
Spirometra erinaceieuropaei. Based on a previous study that was conducted to identify the 
early diagnostic antigens from Spirometra erinaceieuropaei using immunoproteomics 
showed that the Spirometra erinaceieuropaei might have similarty to Toxoplasma gondii, 
(Dan Hu, Xiao et al. 2014) also at this study, suggesting that Toxoplasma gondii might had 
similar gene sequences and common antigen with Spirometra erinaceieuropaei. Thus, the 
immune sera from pregnant women had cross immune reaction with  Spirometra proteins. 
 
Conclusion:  
        In conclusion, the epitopes of Toxoplasma gondii was recognized by immune sera of the 
pregnant women. The identified M13 phage epitopes has the potential for developing a 
suitable Toxoplasma immunological test based on identification of immunoreactive peptides 
of M13 bacteriophage by dot- ELISA and ELISA. The newly identified peptides can 
overcome the high antibody titers seen among negative controls examined by ELISA 
immunoassay. This study also provided a provision supply of Toxoplasma antigenic material 
to be used in an ELISA technique or to be bound on synthetic latex or sheep red blood cells 
in order to perform agglutination test. 
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Appendix A 
---------------------------------------------------------------------------------------------------------------- 
    Peptides coding sequences of the 24 different clones identified by high antibody titer 
Toxoplasma gondii pooled sera 
>ph1 
NNTTTGTCTCCTTCaCgAcGTTAGTAAATGAATTTTCTGTATGGGATTTTGCTAAAC
AACTTTCAACAGTTTCGGCCGAACCTCCACCCTTCTTCTGATGAAGCAACAAACG
ATCCACATCACGAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATAA
TAATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAAT
TGTATCGGTTTATCAGCTTGCTTTCGAGGTGAATAN 
>ph5 
TTTGTcgTCTTCaCgAGTTAGTAAATGAATTTTCTGTATGGGATTTTGCTAAACAAC
TTTCAACAGTTTCGGCCGAACCTCCACCCCtgCATaCaTTCTGANTCCTNGTCATCC
CANNANGACCAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATAAT
AATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAATT
GTATCGGTTTATCAGCTTGCTTTCGAGGTGAATA 
>ph7 
ATTTGTcgTCtTTCaCGACGTTAGTAAATGAATTTTACTGTATGGGCATTTTGCTAA
ACAACTTTCAACAGTTTCGGCCGAACCTCCACCAGCCGGCATATAAGCATGCGAC
TCAGTCAGCCAACCAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAAT
AATAATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGANCNTTTA
NTTGNATCGGNTNATCNGNNTGNNTTCAAGGTGAATCNTATANCCGGNGTGNAN 
>ph8 
TTTGTcgTCTTCaCAcGTTAGTAAATGAATTTTCTGTATGGGATTTTGCTAAACAAC
TTTCAACAGTTTCGGCCGAACCTCCACCCCACCTCAAAACAGTACGACGTAATCA
CCGACCAATCAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATAATA
ATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAATTT
ATCGGTTTATCAGCTTGCTTTCGAGGTGAATA 
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>ph10 
TTTGTCgTCTTCaCgACGTTAGTAAATGAATTTTCTGTATGGGATTTTGCTAAACAA
CTTTCAACAGTTTCGGCCGAACCTCCACCCGCCTACTGNATANNANNATAAGGA
GCCGGAAAANNAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATAA
TAATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAAT
TGTATCGGTTTATCAGCTTGCTTTCGAGGTGAATA 
>ph13 
TTTGTCgTCTTCaCgACGTTAGTAAATGAATTTTCTGTATGGGATTTTGCTAAACAA
CTTTCAACAGTTTCGGCCGAACCTCCACCAGNACCGAACAGAAGCATTAAACGG
AAGCGACTGAATAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATA
ATAATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAA
TTGTATCGGTTTATCAGCTTGCTTTCGAGGTGAATA 
>ph14 
TTTGTcgTCTTCaCgAcGTTAGTAAATGAATTTTCTGTATGGGATTTTGCTAAACAA
CTTTCAACAGTTTCGGCCGAACCTCCACCCCACGGATCCTTCTACAACTCCTCACT
CATCGAATAAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATAATAA
TTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAATTGT
ATCGGTTTATCAGCTTGCTTTCGAGGTGAATA 
>ph18 
TTTGTCgTCTTCaCgAcGTTAGTAAATGAATTTTCTGTATGGGATTTTGCTAAACAA
CTTTCAACAGTTTCGGCCGAACCTCCACCCGGAAGACGACGTAGCACCACTCATA
CGAATAAGATGAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATAAT
AATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAATT
GTATCGGTTTATCAGCTTGCTTTCGAGGTGAATANA 
>ph19 
ATTTTGTcgTCTTTCaCGACGTTAGTAAATGAATTTTCTGTATGGGATTTTGCTAAA
CAACTTTCAACAGTTTCGGCCGAACCTCCACCCTCATTAACCGTCTCAGAATGCT
GATTCACATTAATAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATA
72 
 
ATAATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAA
TTGTATCGGTTTATCAGCTTGCTTTCGAGGTGAATA 
>ph20(old) 
TTTGTcgTCtTTCaCAcGTTAGTAAATGAATTTTCTGTATGGGATTTTGCTAAACAAC
TTTCAACAGTTTCGGCCGAACCTCCACCATCCGGCAAATCCCCACTCTGATAACG
CGTACTAAAAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATAATAA
TTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAATTGT
ATCGGTTTATCAGCTTGCTTTCGAGGTGAATA 
>ph23(old) 
TTTGTcgTCTTTCaCgACGTTAGTAAATGAATTTTCTGTATGGGATTTTGCTAAACA
ACTTTCAACAGTTTCGGCCGAACCTCCACCCAGCCCCCGAGTCTGATGATGAACA
GAATTAAGACTAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATAAT
AATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAATT
GTATCGGTTTATCAGCTTGCTTTCGAGGTGAATA 
>ph24(old) 
TTTGTCgTCtTTCaCgAGTTAGTAAATGAATTTTCTGTATGGGATTTTGCTAAACAA
CTTTCAACAGTTTCGGCCGAACCTCCACCCTTCCGCAGCGTAGGCAGACTCGGAT
CATGATAATCAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATAATA
ATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAATTG
TATCGGTTTATCAGCTTGCTTTCGAGGTGAATA 
>ph21 
ACCNTAANNCNNNTCTCTTGCGTAGTGGGGAAATGAATTNAAANTGTATGGNCT
TTTGCTAAACAACTTTCAACAGTTTCGGCCGAACCTCCACNATGNANCGAATGNG
GTCATGNGGGGGTGTGCTTNGNGTCTGTGTNGNCTCTGCNACGAATTCATGNNNT
GCNCCGANNNAAGGCTAANTGCCGGATNATGGACNTTAGNAGGNGGNCGGNNN
NCGACNANTTGAGGCTTNNNNGANTNGNCCNANCTTNNNCNNGCNNTTNTGGGN 
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>ph22 
NTTTGTNCTCCTTNCCNTACGTTNGTAAATGAATTTTACTGTATGGGCATTTTGCT
AAACAACTTTCAACAGTTTCGGCCGANCNTCCACCNAANNGCNCCTGNAGCNGN
CNNGCATGCTNAACCTTTTAGCTGNNANNAGANCGGNACCACNAAGGNNNNTGC
AGGANCCATTTTTTGCACNNNNNAAANCTCNTGCNAAAGGCGTGAATAAGGAGC
CTTTAATTGTATCGGTTTATCAGCTTGCTTTCGAGGTGAATANNNNNNNNNNNN 
>ph23 
GANTNTTGTACNCCTTNGCNTAGTTGNTAAATGAANTNNTANAGTATGGGNNNN
TTGCTAAACAACTTTCAACAGTTTNNGAACGAGCCTCCACCCTGANAGCGNCTGA
TGGATGACGAGGANGCNTAGNCNTCTGNAGAGACGTNTAGAAAGGGNNCATGG
ATGGGNNTTTNNGAGNNNNAANNGGTGTCTGNGGGTTANTTTCNNNGNTGANGG
GGGGGGNTGNGANCNNGCNTGCGNANNNTNNNGATTAGCACTGGCTTNCNACG
GGGNNNNGAANGNGACTNNNCNTNGNGAANTNNANANCACGCNNGNTCNGN 
>ph24 
ANACGNTTTGTACTCCTTNCCTACGTTGNTAAATGAATTTTACTGTATGGGCATTT
TGCTAAACAACTTTCAACAGTTTCGGCCGAACCTCCACCNANNAACGACTGAAG
CTGCCNACCATGCTTANCCTCGTGAGTGAGAATAGAAAGGTACCACTAANGGAA
TTGCGANTANTAATTTTTNCACGTNGAAAATCTCCANAAAAAAGGCTCCAAAAG
GAGCCTTTAATTGTATCGGTTTATCAGCTTGCTTTCGAGGTGAATAANCNNGCNT 
>ph25 
TNTGTACTCTTCCTAGTTAGTAAATGAATTTTACTGTATGGGATTTTGCTAAACAA
CTTTCAACAGTTTCGGCCGAGCNNCCACCAAAAGGCNCCNGNANCNGANTTGCA
GAGCNAAAANTTTTNCNGGTTGAANATCGGCACCAAAAAGGCNCCTGNNGGAGC
CATTNATTGNANNGGNTTANCNGCNTGCTTNNGNGGTGAATAGGACCCNTNAAT
TGNATCGGTTTATNAGCCNNGCNTTCCNAGGNTGAATAAANTAGGCNNATCNCN
ANGCCTNNNCGTCTTCANCTACNNGTGTNNNTTTANAACNGAGNCCNGCANATA 
>ph26 
GTGNNNCGCGNTCNNGTNANCGNTNNCTNTTNTNCTNTATNNCCNNTGGGNNGG
CGNNTGANNNNNNCCTNNANTNNGGNNTTANNNAANCNNNNNAAANTCTCGNN
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AGCNCNTTNNCNGGGNTNCTNCNNCGGNNTNGGGGGNTTAAAAAAAGCGCAGC
CCCCCCCTCGATNNNNNNNCTTTCTATTTNTTNTNNTGCNCCATGCNGNNTCAGC
NCTGTNGTGCNTNTNTANGANGTGGTTANCGTGANGNTTACTNNANGNAATGGC 
>ph27 
NATTTGTNNTCTTNNCCTAGTTANTAAATGAATTTtctGTATGGGAtTTTGCTAAAC
AACTTTCAACAGTTTCGGCCGAACCTCCACCCGNAANCGNNTGATAGNNTGANN
NANNATGCAGTNNCCGCTNGAGTGACGANTAGAANGGTNACCACATAATGGAAT
TGCNGGATNNATANTNTNTGCANGNTGANAATCTCCNGANAAAAGGCTNNANNN
GGAANNCTTTNATTGGTATCCGGTTTATCNNCTCGCTTTCTNCNTGNANANCNNC
NNNNNAGNCTCAGTCNCGNTANNNTGCGGNTATNNCGNATTNNGTC 
>ph29 
AGACNTNNTGTANTCCTTNCCTAGTTNGTAAATGAATTTTACTGTATGGGATTTT
GCTAAACAACTTTCAACAGTTTCGGCCGAACCTCCACCCAGAAACGTATTCTTAA
GATGAACCGGCNGCGGCTGAGAGTGAGAATAGAAAGGTACCACTAAAGGAATT
GCGAATAATAATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGA
GCCTTTAATTGTATCGGTTTATCAGCTTGCTTTCGAGGTGAATANNNCCAANCAN 
>ph30 
AAACGCTNTGTNNTCTTGCCTTACGTGGNNAAATGAATTTTANTGTATGGGCANT
TTGCTAAACAACTTTCAACAGTTTCGGCCGAACCTCCACCACCCAGCCGACGATC
CNGCTCNGNCNGCNGAATNTGAGAGTGAGAATAGAANGGTACCACTAAAGGAA
TTGCGNATAATANTTTTTTCACGTTGAAAATCTCCAGAAAAAAGGCTCCANAAGG
AGCCTTTAATTGTATCGGTTTATCAGCTTGCTTTCGAGGTGAATAANNCNNNANC
GNGGTNNCNCANTNNTGGTANNGCNGNAGTANNANAANNTNGNCTNG 
>ph31 
NANACNATNTGTNNTCTTNCCTACGTTGGNAAATGAATTTTACTGTATGGGCATT
TTGCTAAACAACTTTCAACAGTTTCGGCCGAACCTCCACCANAANNCGNCTGAN
ANTGCCCANCATGCTNAGNCTCAGAGTGAGAATAGAAAGGTACCACTAANGGAA
TTGCGAATAATAATTTTTNCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAG
GAGCCTTTAATTGTATCGGTTTATCAGCTTGCTTTCGAGGTGAATANNCNAGTNN
GCCTNNCTNTCGGNTTNTTGNTTNCANCTCTGCNNTTTTTTNCGCCNNTGNNTCTN
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CCNNTNCTTGNNGGCCGNANNCTNNCNGNNCCGCNNNCTCCNCCNNTAGTTGNG
ANTGNGCNCNNTTAGNTT 
>ph32 
CNTTTGTACTCTNCCTAGTTNGTAAATGAATTTTCTGTATGGGANTTTGCTAAACA
ACTTTCAACAGTTTCGGCCGAACCTCCACCAATCCTAAAACGCGCATNATTCGTA
AGATCCTTCGAAGAGTGAGAATAGAAAGGTACCACTAAAGGAATTGCGAATAAT
AATTTTTTCACGTTGAAAATCTCCAAAAAAAAGGCTCCAAAAGGAGCCTTTAATT
GTATCGGTTTATCAGCTTGCTTTCGAGGTGAATANNNT 
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